 Thomas Campbell
Concepts (640)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 113 | 2026 | 3022 | 6.220 |
Why?
| | Sarcoma, Kaposi | 25 | 2025 | 80 | 6.020 |
Why?
| | HIV-1 | 61 | 2023 | 895 | 4.400 |
Why?
| | Anti-HIV Agents | 47 | 2024 | 860 | 3.740 |
Why?
| | Herpesvirus 8, Human | 22 | 2024 | 66 | 3.280 |
Why?
| | Antiretroviral Therapy, Highly Active | 30 | 2023 | 285 | 2.470 |
Why?
| | AIDS-Related Opportunistic Infections | 13 | 2024 | 128 | 1.790 |
Why?
| | Anti-Retroviral Agents | 21 | 2024 | 245 | 1.740 |
Why?
| | Acquired Immunodeficiency Syndrome | 7 | 2023 | 235 | 1.370 |
Why?
| | Viral Load | 34 | 2023 | 506 | 1.360 |
Why?
| | Zimbabwe | 18 | 2024 | 61 | 1.310 |
Why?
| | HIV Seropositivity | 7 | 2021 | 127 | 1.310 |
Why?
| | International Cooperation | 4 | 2018 | 203 | 1.150 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1258 | 1.120 |
Why?
| | CD4 Lymphocyte Count | 26 | 2023 | 284 | 1.020 |
Why?
| | Inflammation | 16 | 2025 | 2902 | 1.000 |
Why?
| | Aging | 9 | 2024 | 1924 | 0.970 |
Why?
| | Education, Medical | 3 | 2018 | 271 | 0.960 |
Why?
| | alpha 1-Antichymotrypsin | 1 | 2025 | 4 | 0.910 |
Why?
| | RNA, Viral | 19 | 2014 | 693 | 0.840 |
Why?
| | Physical Fitness | 2 | 2015 | 206 | 0.810 |
Why?
| | Adult | 98 | 2026 | 39391 | 0.810 |
Why?
| | Middle Aged | 75 | 2026 | 34647 | 0.790 |
Why?
| | DNA, Viral | 12 | 2013 | 367 | 0.770 |
Why?
| | Humans | 164 | 2026 | 141754 | 0.770 |
Why?
| | Male | 116 | 2026 | 70179 | 0.760 |
Why?
| | Gastrointestinal Microbiome | 7 | 2026 | 730 | 0.740 |
Why?
| | Tuberculosis | 7 | 2023 | 286 | 0.740 |
Why?
| | Drug Resistance, Viral | 8 | 2015 | 120 | 0.710 |
Why?
| | Herpesviridae Infections | 7 | 2021 | 148 | 0.710 |
Why?
| | Viremia | 6 | 2011 | 150 | 0.710 |
Why?
| | Female | 108 | 2025 | 75943 | 0.690 |
Why?
| | Antibodies, Viral | 8 | 2023 | 656 | 0.680 |
Why?
| | AIDS Dementia Complex | 7 | 2015 | 52 | 0.660 |
Why?
| | Coinfection | 6 | 2019 | 137 | 0.660 |
Why?
| | CD4-Positive T-Lymphocytes | 12 | 2023 | 1115 | 0.660 |
Why?
| | Granulocyte Colony-Stimulating Factor | 4 | 2004 | 89 | 0.620 |
Why?
| | Reverse Transcriptase Inhibitors | 6 | 2015 | 87 | 0.620 |
Why?
| | Nursing Staff, Hospital | 1 | 2022 | 161 | 0.610 |
Why?
| | Lamivudine | 6 | 2017 | 65 | 0.610 |
Why?
| | Hematopoietic Stem Cell Mobilization | 3 | 2004 | 27 | 0.600 |
Why?
| | Lipopolysaccharide Receptors | 2 | 2021 | 91 | 0.600 |
Why?
| | Homosexuality, Male | 6 | 2026 | 209 | 0.590 |
Why?
| | Anemia | 3 | 2023 | 177 | 0.580 |
Why?
| | Vitamin D Deficiency | 3 | 2017 | 190 | 0.570 |
Why?
| | HIV | 8 | 2023 | 250 | 0.550 |
Why?
| | Vitamin D | 5 | 2018 | 397 | 0.550 |
Why?
| | Plasma | 4 | 2015 | 221 | 0.510 |
Why?
| | Micronutrients | 4 | 2018 | 92 | 0.500 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2023 | 23 | 0.500 |
Why?
| | Health Resources | 5 | 2019 | 129 | 0.490 |
Why?
| | Internationality | 5 | 2019 | 158 | 0.480 |
Why?
| | Breast Neoplasms | 2 | 2025 | 2257 | 0.470 |
Why?
| | Motor Activity | 3 | 2015 | 720 | 0.470 |
Why?
| | Prospective Studies | 21 | 2022 | 7777 | 0.460 |
Why?
| | RNA, Catalytic | 4 | 1997 | 189 | 0.460 |
Why?
| | Burnout, Professional | 1 | 2022 | 459 | 0.450 |
Why?
| | Awareness | 1 | 2015 | 103 | 0.450 |
Why?
| | Developing Countries | 10 | 2020 | 318 | 0.450 |
Why?
| | Benzoxazines | 6 | 2017 | 34 | 0.440 |
Why?
| | Zidovudine | 7 | 2017 | 79 | 0.430 |
Why?
| | Antibiotics, Antineoplastic | 3 | 2023 | 131 | 0.430 |
Why?
| | Quality of Life | 6 | 2019 | 3014 | 0.430 |
Why?
| | Lung Neoplasms | 2 | 2025 | 2567 | 0.420 |
Why?
| | HIV Integrase Inhibitors | 1 | 2015 | 72 | 0.420 |
Why?
| | C-Reactive Protein | 5 | 2015 | 424 | 0.410 |
Why?
| | Bronchoalveolar Lavage Fluid | 6 | 2021 | 650 | 0.410 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 197 | 0.410 |
Why?
| | Monocytes | 2 | 2023 | 579 | 0.400 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 4 | 2020 | 19 | 0.380 |
Why?
| | Prevotella | 2 | 2025 | 26 | 0.380 |
Why?
| | Biomarkers | 13 | 2023 | 4190 | 0.380 |
Why?
| | Aged | 24 | 2025 | 24746 | 0.370 |
Why?
| | Treatment Outcome | 22 | 2023 | 11181 | 0.370 |
Why?
| | Disease Progression | 11 | 2025 | 2800 | 0.370 |
Why?
| | Sarcopenia | 1 | 2013 | 82 | 0.360 |
Why?
| | Receptors, CCR5 | 5 | 2021 | 61 | 0.360 |
Why?
| | Malnutrition | 3 | 2018 | 85 | 0.350 |
Why?
| | Case-Control Studies | 9 | 2025 | 3597 | 0.350 |
Why?
| | Faculty, Medical | 4 | 2018 | 296 | 0.330 |
Why?
| | South America | 7 | 2020 | 60 | 0.320 |
Why?
| | Osteoporosis | 1 | 2013 | 244 | 0.320 |
Why?
| | Africa | 6 | 2020 | 119 | 0.320 |
Why?
| | Accidental Falls | 1 | 2012 | 216 | 0.320 |
Why?
| | Neutropenia | 1 | 2010 | 157 | 0.310 |
Why?
| | Antineoplastic Agents, Phytogenic | 3 | 2020 | 192 | 0.310 |
Why?
| | Antiviral Agents | 5 | 2017 | 747 | 0.310 |
Why?
| | Drug Therapy, Combination | 10 | 2020 | 1041 | 0.310 |
Why?
| | Sexual Behavior | 4 | 2020 | 498 | 0.310 |
Why?
| | Virus Replication | 6 | 2006 | 532 | 0.310 |
Why?
| | Cross-Sectional Studies | 10 | 2022 | 5697 | 0.300 |
Why?
| | Tenofovir | 6 | 2017 | 285 | 0.300 |
Why?
| | Emergency Medical Services | 1 | 2015 | 650 | 0.290 |
Why?
| | Randomized Controlled Trials as Topic | 9 | 2025 | 1634 | 0.290 |
Why?
| | Advance Care Planning | 1 | 2012 | 223 | 0.290 |
Why?
| | Thrombocytopenia | 1 | 2010 | 208 | 0.290 |
Why?
| | Viral Proteins | 2 | 2008 | 369 | 0.280 |
Why?
| | Pharmacogenetics | 3 | 2023 | 168 | 0.280 |
Why?
| | Genetic Variation | 4 | 2008 | 1000 | 0.280 |
Why?
| | Health Services Accessibility | 1 | 2015 | 1027 | 0.270 |
Why?
| | Etoposide | 4 | 2023 | 164 | 0.270 |
Why?
| | Professional Competence | 2 | 2018 | 97 | 0.270 |
Why?
| | Microbiota | 4 | 2018 | 768 | 0.270 |
Why?
| | Sex Characteristics | 3 | 2023 | 792 | 0.260 |
Why?
| | Atazanavir Sulfate | 3 | 2016 | 44 | 0.260 |
Why?
| | Sexual and Gender Minorities | 3 | 2021 | 234 | 0.260 |
Why?
| | Cohort Studies | 20 | 2019 | 5815 | 0.260 |
Why?
| | Cyclopropanes | 6 | 2017 | 78 | 0.260 |
Why?
| | Schools, Medical | 2 | 2018 | 152 | 0.260 |
Why?
| | Survival Analysis | 4 | 2015 | 1320 | 0.260 |
Why?
| | Alkynes | 6 | 2017 | 66 | 0.260 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1406 | 0.260 |
Why?
| | Drug Monitoring | 1 | 2010 | 399 | 0.250 |
Why?
| | Macrophages, Alveolar | 2 | 2020 | 396 | 0.250 |
Why?
| | Asia | 5 | 2016 | 70 | 0.250 |
Why?
| | Feces | 5 | 2025 | 505 | 0.240 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2021 | 918 | 0.240 |
Why?
| | Sex Factors | 4 | 2016 | 2063 | 0.240 |
Why?
| | Treatment Failure | 8 | 2018 | 354 | 0.240 |
Why?
| | Genotype | 7 | 2023 | 1866 | 0.240 |
Why?
| | Risk Factors | 17 | 2024 | 10482 | 0.230 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2005 | 10 | 0.230 |
Why?
| | Needs Assessment | 2 | 2018 | 385 | 0.230 |
Why?
| | Pregnancy Complications, Infectious | 3 | 2018 | 408 | 0.230 |
Why?
| | Young Adult | 19 | 2023 | 13749 | 0.230 |
Why?
| | Body Composition | 2 | 2020 | 703 | 0.220 |
Why?
| | Proportional Hazards Models | 7 | 2018 | 1268 | 0.220 |
Why?
| | Immune System Diseases | 1 | 2004 | 40 | 0.220 |
Why?
| | Virus Latency | 1 | 2004 | 80 | 0.210 |
Why?
| | Salvage Therapy | 1 | 2005 | 154 | 0.210 |
Why?
| | Xenobiotics | 1 | 2024 | 32 | 0.210 |
Why?
| | Dideoxynucleosides | 2 | 2014 | 21 | 0.210 |
Why?
| | Lymph Nodes | 3 | 2011 | 502 | 0.210 |
Why?
| | Curriculum | 4 | 2018 | 1039 | 0.200 |
Why?
| | Cardiotoxicity | 1 | 2023 | 26 | 0.200 |
Why?
| | Program Evaluation | 2 | 2018 | 930 | 0.200 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2017 | 325 | 0.200 |
Why?
| | Heart Injuries | 1 | 2023 | 40 | 0.200 |
Why?
| | Interleukin-10 | 2 | 2023 | 310 | 0.190 |
Why?
| | ADP-ribosyl Cyclase 1 | 2 | 2013 | 42 | 0.190 |
Why?
| | Intestinal Mucosa | 2 | 2021 | 632 | 0.190 |
Why?
| | Lung | 8 | 2022 | 4137 | 0.190 |
Why?
| | Neurocognitive Disorders | 2 | 2019 | 30 | 0.190 |
Why?
| | Nevirapine | 2 | 2013 | 18 | 0.190 |
Why?
| | Prevalence | 9 | 2019 | 2799 | 0.190 |
Why?
| | Plaque, Atherosclerotic | 1 | 2023 | 58 | 0.180 |
Why?
| | Incidence | 7 | 2023 | 2806 | 0.180 |
Why?
| | Myocarditis | 1 | 2023 | 100 | 0.180 |
Why?
| | United States | 9 | 2023 | 15310 | 0.180 |
Why?
| | Research Design | 2 | 2025 | 1146 | 0.180 |
Why?
| | Personnel Turnover | 1 | 2022 | 38 | 0.180 |
Why?
| | Speech | 1 | 2022 | 74 | 0.180 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 34 | 0.180 |
Why?
| | Surveys and Questionnaires | 5 | 2022 | 5974 | 0.180 |
Why?
| | Lymphocytes | 2 | 2023 | 398 | 0.180 |
Why?
| | Polymerase Chain Reaction | 6 | 2021 | 1056 | 0.180 |
Why?
| | Adolescent | 16 | 2023 | 22130 | 0.180 |
Why?
| | Emtricitabine | 4 | 2017 | 205 | 0.180 |
Why?
| | Gastrointestinal Tract | 2 | 2014 | 204 | 0.170 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2022 | 98 | 0.170 |
Why?
| | B-Cell Maturation Antigen | 1 | 2021 | 13 | 0.170 |
Why?
| | Selenium | 3 | 2018 | 49 | 0.170 |
Why?
| | Multivariate Analysis | 4 | 2015 | 1498 | 0.170 |
Why?
| | Cognition | 4 | 2017 | 1228 | 0.170 |
Why?
| | Doxorubicin | 1 | 2023 | 360 | 0.170 |
Why?
| | Thinking | 1 | 2021 | 69 | 0.160 |
Why?
| | Odds Ratio | 2 | 2014 | 1057 | 0.160 |
Why?
| | Filgrastim | 4 | 2004 | 12 | 0.160 |
Why?
| | Longitudinal Studies | 9 | 2019 | 2938 | 0.160 |
Why?
| | T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2020 | 7 | 0.160 |
Why?
| | Leukapheresis | 1 | 2000 | 26 | 0.160 |
Why?
| | Intention | 1 | 2022 | 179 | 0.160 |
Why?
| | Pilot Projects | 5 | 2014 | 1826 | 0.160 |
Why?
| | Pyridazines | 2 | 2012 | 56 | 0.160 |
Why?
| | Hematopoietic Stem Cells | 2 | 2000 | 411 | 0.160 |
Why?
| | Vincristine | 1 | 2020 | 132 | 0.150 |
Why?
| | Membrane Glycoproteins | 2 | 2013 | 502 | 0.150 |
Why?
| | Workplace | 1 | 2022 | 269 | 0.150 |
Why?
| | Leadership | 3 | 2018 | 399 | 0.150 |
Why?
| | Job Satisfaction | 1 | 2022 | 224 | 0.150 |
Why?
| | Weight Loss | 3 | 2020 | 791 | 0.150 |
Why?
| | B-Lymphocytes | 1 | 2004 | 859 | 0.150 |
Why?
| | Germ-Free Life | 1 | 2019 | 33 | 0.150 |
Why?
| | Bacteria | 3 | 2018 | 881 | 0.150 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2020 | 132 | 0.150 |
Why?
| | Hexosaminidases | 1 | 2019 | 18 | 0.150 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 663 | 0.150 |
Why?
| | Exercise | 2 | 2021 | 2112 | 0.150 |
Why?
| | DNA Methylation | 1 | 2024 | 648 | 0.150 |
Why?
| | Clinical Trials as Topic | 2 | 2016 | 1057 | 0.150 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2021 | 394 | 0.150 |
Why?
| | Atherosclerosis | 1 | 2023 | 404 | 0.150 |
Why?
| | Basal Ganglia | 3 | 2014 | 57 | 0.140 |
Why?
| | Brain | 4 | 2019 | 2868 | 0.140 |
Why?
| | Bleomycin | 1 | 2020 | 248 | 0.140 |
Why?
| | Violence | 1 | 2022 | 276 | 0.140 |
Why?
| | Suicide | 2 | 2017 | 671 | 0.140 |
Why?
| | Cerebral Cortex | 2 | 2013 | 462 | 0.140 |
Why?
| | Urban Population | 2 | 2013 | 485 | 0.140 |
Why?
| | Organophosphonates | 3 | 2013 | 99 | 0.140 |
Why?
| | Genes, pol | 3 | 2007 | 7 | 0.140 |
Why?
| | Mutation | 5 | 2016 | 4015 | 0.140 |
Why?
| | Mouth | 2 | 2015 | 88 | 0.140 |
Why?
| | AIDS Vaccines | 1 | 2018 | 53 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1138 | 0.140 |
Why?
| | Multiple Myeloma | 1 | 2021 | 283 | 0.130 |
Why?
| | Capacity Building | 1 | 2018 | 62 | 0.130 |
Why?
| | Drug Combinations | 2 | 2017 | 368 | 0.130 |
Why?
| | HIV Protease Inhibitors | 2 | 2016 | 68 | 0.130 |
Why?
| | Nucleic Acid Conformation | 2 | 1997 | 725 | 0.130 |
Why?
| | Vitamin A Deficiency | 1 | 2017 | 27 | 0.130 |
Why?
| | Early Detection of Cancer | 1 | 2022 | 444 | 0.130 |
Why?
| | Didanosine | 2 | 2014 | 13 | 0.130 |
Why?
| | Herpesvirus 2, Human | 1 | 2017 | 29 | 0.130 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2017 | 101 | 0.130 |
Why?
| | Follow-Up Studies | 7 | 2021 | 5212 | 0.130 |
Why?
| | Brain Injuries, Traumatic | 1 | 2023 | 400 | 0.130 |
Why?
| | Inflammation Mediators | 2 | 2018 | 519 | 0.130 |
Why?
| | Immunotherapy, Adoptive | 1 | 2021 | 360 | 0.130 |
Why?
| | Dysbiosis | 2 | 2021 | 180 | 0.130 |
Why?
| | Financing, Organized | 1 | 2017 | 39 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 482 | 0.130 |
Why?
| | Hospitals | 1 | 2022 | 696 | 0.130 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 198 | 0.130 |
Why?
| | Recombinant Proteins | 4 | 2004 | 1363 | 0.120 |
Why?
| | Africa South of the Sahara | 4 | 2020 | 46 | 0.120 |
Why?
| | Haiti | 2 | 2016 | 11 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2023 | 702 | 0.120 |
Why?
| | Adenine | 3 | 2013 | 331 | 0.120 |
Why?
| | Genes, env | 2 | 2007 | 5 | 0.120 |
Why?
| | Herpes Simplex | 1 | 2017 | 95 | 0.120 |
Why?
| | Cognitive Dysfunction | 2 | 2019 | 412 | 0.120 |
Why?
| | Immunoglobulin G | 2 | 2023 | 900 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 3 | 2013 | 910 | 0.120 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2014 | 614 | 0.120 |
Why?
| | Nervous System Diseases | 1 | 2019 | 277 | 0.120 |
Why?
| | Tetrahymena thermophila | 1 | 1996 | 65 | 0.120 |
Why?
| | Lymphocyte Activation | 3 | 2018 | 1150 | 0.120 |
Why?
| | Ghana | 1 | 2015 | 38 | 0.120 |
Why?
| | Mental Status and Dementia Tests | 1 | 2016 | 27 | 0.120 |
Why?
| | Up-Regulation | 1 | 2019 | 860 | 0.120 |
Why?
| | TRPP Cation Channels | 1 | 2016 | 81 | 0.120 |
Why?
| | Molecular Sequence Data | 6 | 2013 | 2929 | 0.120 |
Why?
| | Liver | 1 | 2024 | 1820 | 0.120 |
Why?
| | Military Personnel | 1 | 2023 | 615 | 0.120 |
Why?
| | Ambulances | 1 | 2015 | 52 | 0.120 |
Why?
| | Muscle Strength | 1 | 2018 | 329 | 0.120 |
Why?
| | DNA, Protozoan | 1 | 2015 | 32 | 0.120 |
Why?
| | RNA, Protozoan | 1 | 1995 | 60 | 0.120 |
Why?
| | Hepatitis B, Chronic | 1 | 2015 | 21 | 0.120 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 457 | 0.120 |
Why?
| | Plasmodium falciparum | 1 | 2015 | 34 | 0.110 |
Why?
| | Rhodobacter sphaeroides | 3 | 1983 | 7 | 0.110 |
Why?
| | Chemokine CXCL10 | 1 | 2015 | 38 | 0.110 |
Why?
| | Clinical Competence | 2 | 2021 | 1205 | 0.110 |
Why?
| | Cerebrospinal Fluid | 1 | 2015 | 92 | 0.110 |
Why?
| | Retroviridae Infections | 1 | 1995 | 48 | 0.110 |
Why?
| | Malaria | 1 | 2015 | 66 | 0.110 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2015 | 139 | 0.110 |
Why?
| | Research | 1 | 2018 | 455 | 0.110 |
Why?
| | Anthracyclines | 1 | 2014 | 43 | 0.110 |
Why?
| | Cytomegalovirus | 1 | 2015 | 163 | 0.110 |
Why?
| | Health Occupations | 1 | 2014 | 34 | 0.110 |
Why?
| | Orchitis | 1 | 2014 | 5 | 0.110 |
Why?
| | Penicillin G | 1 | 2014 | 7 | 0.110 |
Why?
| | Time Factors | 3 | 2015 | 6966 | 0.110 |
Why?
| | Caribbean Region | 2 | 2011 | 29 | 0.110 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2017 | 240 | 0.110 |
Why?
| | Exercise Therapy | 1 | 2018 | 454 | 0.100 |
Why?
| | Health Care Surveys | 1 | 2015 | 566 | 0.100 |
Why?
| | Stavudine | 1 | 2013 | 8 | 0.100 |
Why?
| | Syphilis | 1 | 2014 | 35 | 0.100 |
Why?
| | Seroepidemiologic Studies | 2 | 2015 | 168 | 0.100 |
Why?
| | Biota | 1 | 2013 | 35 | 0.100 |
Why?
| | Tropheryma | 1 | 2013 | 7 | 0.100 |
Why?
| | HIV Antigens | 3 | 2015 | 18 | 0.100 |
Why?
| | Whipple Disease | 1 | 2013 | 8 | 0.100 |
Why?
| | Phylogeny | 3 | 2008 | 1019 | 0.100 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 36 | 0.100 |
Why?
| | Pyrrolidinones | 1 | 2013 | 30 | 0.100 |
Why?
| | Aging, Premature | 1 | 2013 | 16 | 0.100 |
Why?
| | Metabolic Diseases | 1 | 2014 | 114 | 0.100 |
Why?
| | Genitalia, Male | 1 | 2013 | 11 | 0.100 |
Why?
| | Body Fat Distribution | 1 | 2013 | 48 | 0.100 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2012 | 186 | 0.100 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 454 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 526 | 0.100 |
Why?
| | Retinal Detachment | 1 | 2014 | 74 | 0.100 |
Why?
| | Problem-Based Learning | 1 | 2014 | 99 | 0.100 |
Why?
| | Peptide Fragments | 3 | 2007 | 701 | 0.100 |
Why?
| | Genitalia, Female | 1 | 2013 | 41 | 0.100 |
Why?
| | Hospitals, University | 1 | 2013 | 175 | 0.100 |
Why?
| | Sequence Analysis, DNA | 3 | 2013 | 825 | 0.100 |
Why?
| | Fever | 2 | 2021 | 308 | 0.100 |
Why?
| | Genetic Therapy | 1 | 1995 | 315 | 0.100 |
Why?
| | Suicidal Ideation | 2 | 2017 | 545 | 0.090 |
Why?
| | Pregnancy | 5 | 2018 | 7092 | 0.090 |
Why?
| | Hepatitis B | 1 | 2013 | 69 | 0.090 |
Why?
| | Frail Elderly | 1 | 2013 | 133 | 0.090 |
Why?
| | RNA Stability | 1 | 2013 | 116 | 0.090 |
Why?
| | Metagenome | 1 | 2013 | 152 | 0.090 |
Why?
| | Prostatitis | 1 | 1992 | 18 | 0.090 |
Why?
| | Aspergillosis | 1 | 1992 | 22 | 0.090 |
Why?
| | Muscles | 1 | 2013 | 333 | 0.090 |
Why?
| | Weight Gain | 1 | 2016 | 539 | 0.090 |
Why?
| | Withholding Treatment | 1 | 2012 | 78 | 0.090 |
Why?
| | Movement | 1 | 2014 | 290 | 0.090 |
Why?
| | Urinary Catheterization | 1 | 1992 | 37 | 0.090 |
Why?
| | Respiratory System | 1 | 2013 | 157 | 0.090 |
Why?
| | Unsafe Sex | 1 | 2012 | 63 | 0.090 |
Why?
| | Catheters, Indwelling | 1 | 1992 | 90 | 0.090 |
Why?
| | Universities | 1 | 2014 | 454 | 0.090 |
Why?
| | HIV Core Protein p24 | 3 | 2006 | 32 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 263 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2012 | 329 | 0.090 |
Why?
| | Body Weight | 1 | 2016 | 997 | 0.090 |
Why?
| | Exanthema | 1 | 2012 | 81 | 0.090 |
Why?
| | Paclitaxel | 2 | 2020 | 237 | 0.090 |
Why?
| | Education, Medical, Undergraduate | 1 | 2014 | 196 | 0.090 |
Why?
| | Lipopolysaccharides | 1 | 2015 | 889 | 0.090 |
Why?
| | Neuropsychological Tests | 4 | 2019 | 1093 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1250 | 0.090 |
Why?
| | CD4 Antigens | 1 | 2011 | 141 | 0.090 |
Why?
| | Mycobacterium tuberculosis | 2 | 2012 | 320 | 0.090 |
Why?
| | Polyneuropathies | 1 | 2011 | 57 | 0.090 |
Why?
| | Corpus Callosum | 1 | 2011 | 70 | 0.080 |
Why?
| | Americas | 1 | 2010 | 28 | 0.080 |
Why?
| | Veterans | 1 | 2023 | 1525 | 0.080 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 1048 | 0.080 |
Why?
| | Piperazines | 1 | 1993 | 373 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2014 | 409 | 0.080 |
Why?
| | Body Mass Index | 3 | 2014 | 2385 | 0.080 |
Why?
| | T-Lymphocyte Subsets | 2 | 2011 | 415 | 0.080 |
Why?
| | Smoking | 2 | 2020 | 1603 | 0.080 |
Why?
| | Colon | 2 | 2026 | 300 | 0.080 |
Why?
| | Endothelial Cells | 2 | 2024 | 816 | 0.080 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2019 | 558 | 0.080 |
Why?
| | HLA-DR Antigens | 1 | 2011 | 228 | 0.080 |
Why?
| | Bone and Bones | 1 | 2013 | 317 | 0.080 |
Why?
| | Antigens, Viral | 2 | 2021 | 179 | 0.080 |
Why?
| | Fluorescent Antibody Technique | 3 | 2015 | 386 | 0.080 |
Why?
| | Specimen Handling | 1 | 2011 | 182 | 0.080 |
Why?
| | HIV Reverse Transcriptase | 2 | 2004 | 31 | 0.080 |
Why?
| | Patient Compliance | 1 | 2014 | 611 | 0.080 |
Why?
| | Interleukin-6 | 3 | 2022 | 792 | 0.080 |
Why?
| | HIV Fusion Inhibitors | 2 | 2007 | 3 | 0.080 |
Why?
| | HIV Envelope Protein gp41 | 2 | 2007 | 11 | 0.080 |
Why?
| | Tuberculosis, Pulmonary | 2 | 2013 | 130 | 0.080 |
Why?
| | Emigrants and Immigrants | 1 | 2012 | 149 | 0.080 |
Why?
| | Bone Density | 1 | 2013 | 495 | 0.080 |
Why?
| | Health Personnel | 1 | 2016 | 738 | 0.070 |
Why?
| | Metabolic Syndrome | 1 | 2012 | 349 | 0.070 |
Why?
| | Smokers | 2 | 2020 | 144 | 0.070 |
Why?
| | Neuroimaging | 1 | 2011 | 281 | 0.070 |
Why?
| | RNA | 1 | 1995 | 930 | 0.070 |
Why?
| | South Africa | 3 | 2016 | 240 | 0.070 |
Why?
| | Uganda | 1 | 2008 | 87 | 0.070 |
Why?
| | Lung Diseases | 1 | 2015 | 793 | 0.070 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2006 | 184 | 0.070 |
Why?
| | Leukocytes, Mononuclear | 2 | 2021 | 574 | 0.070 |
Why?
| | Cytokines | 3 | 2021 | 2100 | 0.070 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1317 | 0.070 |
Why?
| | Base Composition | 2 | 1997 | 79 | 0.070 |
Why?
| | Sweating | 1 | 2007 | 41 | 0.060 |
Why?
| | Blood Vessels | 1 | 2008 | 180 | 0.060 |
Why?
| | Amino Acid Sequence | 3 | 2006 | 2158 | 0.060 |
Why?
| | Vitamin A | 2 | 2018 | 57 | 0.060 |
Why?
| | Organizational Culture | 2 | 2018 | 162 | 0.060 |
Why?
| | Healthy Volunteers | 2 | 2018 | 215 | 0.060 |
Why?
| | Purine Nucleosides | 1 | 2006 | 3 | 0.060 |
Why?
| | Dioxolanes | 1 | 2006 | 6 | 0.060 |
Why?
| | Colorado | 3 | 2012 | 4629 | 0.060 |
Why?
| | Gender Identity | 1 | 2007 | 127 | 0.060 |
Why?
| | Peru | 2 | 2016 | 61 | 0.060 |
Why?
| | Gene Products, gag | 1 | 2006 | 38 | 0.060 |
Why?
| | Program Development | 2 | 2018 | 368 | 0.060 |
Why?
| | Substrate Specificity | 2 | 1997 | 385 | 0.060 |
Why?
| | DNA, Bacterial | 3 | 2019 | 339 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2023 | 16374 | 0.060 |
Why?
| | Biopsy | 2 | 2020 | 1083 | 0.060 |
Why?
| | Phospholipids | 3 | 1983 | 221 | 0.060 |
Why?
| | Logistic Models | 3 | 2015 | 2092 | 0.060 |
Why?
| | Selection Bias | 1 | 2005 | 41 | 0.060 |
Why?
| | Disease Reservoirs | 1 | 2004 | 25 | 0.060 |
Why?
| | Dizziness | 2 | 2018 | 94 | 0.060 |
Why?
| | Hypoalbuminemia | 1 | 2024 | 31 | 0.060 |
Why?
| | HIV Protease | 1 | 2004 | 4 | 0.060 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 2024 | 14 | 0.050 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2004 | 61 | 0.050 |
Why?
| | Double-Blind Method | 3 | 2018 | 1989 | 0.050 |
Why?
| | Linear Models | 3 | 2011 | 858 | 0.050 |
Why?
| | Comorbidity | 1 | 2009 | 1664 | 0.050 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2024 | 21 | 0.050 |
Why?
| | WT1 Proteins | 1 | 2024 | 15 | 0.050 |
Why?
| | Base Sequence | 3 | 1996 | 2180 | 0.050 |
Why?
| | Syndrome | 1 | 2004 | 378 | 0.050 |
Why?
| | Castleman Disease | 1 | 2003 | 13 | 0.050 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2023 | 57 | 0.050 |
Why?
| | Animals | 7 | 2024 | 37749 | 0.050 |
Why?
| | Aspartic Acid | 2 | 2014 | 81 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1866 | 0.050 |
Why?
| | Glucuronosyltransferase | 1 | 2023 | 17 | 0.050 |
Why?
| | Endemic Diseases | 1 | 2003 | 36 | 0.050 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2023 | 166 | 0.050 |
Why?
| | Reference Values | 2 | 2016 | 807 | 0.050 |
Why?
| | United Kingdom | 2 | 2014 | 322 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2023 | 2135 | 0.050 |
Why?
| | Speech Intelligibility | 1 | 2022 | 4 | 0.050 |
Why?
| | Speech Production Measurement | 1 | 2022 | 12 | 0.050 |
Why?
| | Binding Sites | 2 | 1996 | 1316 | 0.050 |
Why?
| | Choline | 2 | 2014 | 133 | 0.050 |
Why?
| | Lip | 1 | 2022 | 24 | 0.050 |
Why?
| | Jaw | 1 | 2022 | 26 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2006 | 792 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2024 | 398 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 987 | 0.050 |
Why?
| | Lopinavir | 2 | 2013 | 31 | 0.050 |
Why?
| | Tongue | 1 | 2022 | 82 | 0.050 |
Why?
| | Chemoradiotherapy | 1 | 2023 | 234 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2011 | 3737 | 0.050 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 76 | 0.040 |
Why?
| | Ritonavir | 2 | 2013 | 75 | 0.040 |
Why?
| | Deoxycytidine | 2 | 2014 | 200 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 667 | 0.040 |
Why?
| | Patient Acuity | 1 | 2021 | 47 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2021 | 92 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 44 | 0.040 |
Why?
| | Vidarabine | 1 | 2021 | 35 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2096 | 0.040 |
Why?
| | Frontal Lobe | 2 | 2014 | 163 | 0.040 |
Why?
| | Hemoglobins | 1 | 2023 | 361 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2001 | 174 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 84 | 0.040 |
Why?
| | Reproducibility of Results | 3 | 2008 | 3356 | 0.040 |
Why?
| | Regression Analysis | 2 | 2014 | 1023 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2021 | 289 | 0.040 |
Why?
| | Antibodies, Neutralizing | 1 | 2023 | 323 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2023 | 554 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2021 | 257 | 0.040 |
Why?
| | Cell Line | 3 | 2001 | 2887 | 0.040 |
Why?
| | Integrin alpha Chains | 1 | 2020 | 24 | 0.040 |
Why?
| | Cells, Cultured | 4 | 2008 | 4212 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2007 | 1977 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 855 | 0.040 |
Why?
| | Echocardiography | 1 | 2023 | 648 | 0.040 |
Why?
| | Cough | 1 | 2021 | 133 | 0.040 |
Why?
| | Antigens, CD34 | 1 | 2000 | 89 | 0.040 |
Why?
| | Fatty Acids | 1 | 1983 | 450 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2021 | 150 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2026 | 852 | 0.040 |
Why?
| | Brazil | 2 | 2016 | 173 | 0.040 |
Why?
| | Virion | 1 | 2000 | 113 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 703 | 0.040 |
Why?
| | Immunologic Memory | 1 | 2001 | 360 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2020 | 329 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2022 | 839 | 0.040 |
Why?
| | Nitriles | 2 | 2012 | 188 | 0.040 |
Why?
| | Diffusion Tensor Imaging | 1 | 2019 | 78 | 0.040 |
Why?
| | Teacher Training | 1 | 2018 | 7 | 0.040 |
Why?
| | Atrophy | 1 | 2019 | 197 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 2018 | 86 | 0.040 |
Why?
| | Genes, vpr | 1 | 1997 | 1 | 0.040 |
Why?
| | Genes, vif | 1 | 1997 | 3 | 0.040 |
Why?
| | Motor Skills | 1 | 2019 | 103 | 0.040 |
Why?
| | Trace Elements | 1 | 2018 | 51 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 123 | 0.030 |
Why?
| | Back Pain | 1 | 2018 | 52 | 0.030 |
Why?
| | Stillbirth | 1 | 2018 | 74 | 0.030 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2017 | 10 | 0.030 |
Why?
| | DNA Primers | 2 | 1996 | 510 | 0.030 |
Why?
| | Cytochrome P-450 CYP2A6 | 1 | 2017 | 10 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2018 | 189 | 0.030 |
Why?
| | Adenoviridae | 1 | 2018 | 201 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2018 | 198 | 0.030 |
Why?
| | Immunity, Humoral | 1 | 2018 | 117 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2024 | 1406 | 0.030 |
Why?
| | Diarrhea | 1 | 2018 | 184 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2019 | 1094 | 0.030 |
Why?
| | Toll-Like Receptors | 1 | 2018 | 189 | 0.030 |
Why?
| | Abdominal Pain | 1 | 2018 | 145 | 0.030 |
Why?
| | Seroconversion | 1 | 2017 | 46 | 0.030 |
Why?
| | Genetic Vectors | 1 | 2018 | 336 | 0.030 |
Why?
| | Antigens, CD | 1 | 2020 | 545 | 0.030 |
Why?
| | Oligoribonucleotides | 1 | 1996 | 52 | 0.030 |
Why?
| | Benzoxazoles | 1 | 1996 | 20 | 0.030 |
Why?
| | Immunity, Cellular | 1 | 2018 | 269 | 0.030 |
Why?
| | Ruthenium Red | 1 | 2016 | 7 | 0.030 |
Why?
| | Amiloride | 1 | 2016 | 27 | 0.030 |
Why?
| | Thailand | 1 | 2016 | 17 | 0.030 |
Why?
| | Gene Frequency | 1 | 2017 | 494 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 339 | 0.030 |
Why?
| | Pyrimidines | 2 | 2012 | 512 | 0.030 |
Why?
| | Malawi | 1 | 2016 | 52 | 0.030 |
Why?
| | Life Style | 1 | 2018 | 482 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2021 | 855 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 803 | 0.030 |
Why?
| | Patient Selection | 1 | 2000 | 688 | 0.030 |
Why?
| | India | 1 | 2016 | 208 | 0.030 |
Why?
| | Verbal Learning | 1 | 2016 | 66 | 0.030 |
Why?
| | Age Factors | 2 | 2016 | 3294 | 0.030 |
Why?
| | Catalysis | 1 | 1996 | 320 | 0.030 |
Why?
| | Parasitemia | 1 | 2015 | 14 | 0.030 |
Why?
| | Human Activities | 1 | 2015 | 20 | 0.030 |
Why?
| | pol Gene Products, Human Immunodeficiency Virus | 1 | 2015 | 1 | 0.030 |
Why?
| | Nutritional Status | 1 | 2018 | 362 | 0.030 |
Why?
| | Hepatitis B virus | 1 | 2015 | 33 | 0.030 |
Why?
| | Point Mutation | 1 | 2016 | 237 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2016 | 333 | 0.030 |
Why?
| | Tetrahymena | 1 | 1995 | 157 | 0.030 |
Why?
| | Carotenoids | 1 | 2015 | 42 | 0.030 |
Why?
| | Placebos | 1 | 2015 | 198 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2015 | 73 | 0.030 |
Why?
| | RNA Splicing | 1 | 1996 | 270 | 0.030 |
Why?
| | Pyridones | 1 | 1996 | 188 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 1999 | 719 | 0.030 |
Why?
| | Chronic Disease | 2 | 2014 | 1820 | 0.030 |
Why?
| | Vitamin E | 1 | 2015 | 123 | 0.030 |
Why?
| | Schools, Health Occupations | 1 | 2014 | 8 | 0.030 |
Why?
| | Fellowships and Scholarships | 1 | 2018 | 323 | 0.030 |
Why?
| | Retreatment | 1 | 2014 | 73 | 0.030 |
Why?
| | Mice | 2 | 2024 | 18109 | 0.030 |
Why?
| | Premature Birth | 1 | 2018 | 368 | 0.030 |
Why?
| | Genetic Markers | 1 | 2015 | 343 | 0.030 |
Why?
| | Developed Countries | 1 | 2014 | 39 | 0.030 |
Why?
| | World Health Organization | 1 | 2014 | 126 | 0.030 |
Why?
| | Ophthalmoscopy | 1 | 2014 | 38 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1472 | 0.030 |
Why?
| | Creatine | 1 | 2014 | 62 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2064 | 0.030 |
Why?
| | Psychology | 1 | 2014 | 89 | 0.030 |
Why?
| | Diffusion of Innovation | 1 | 2014 | 97 | 0.030 |
Why?
| | Protons | 1 | 2014 | 94 | 0.030 |
Why?
| | Group Processes | 1 | 2014 | 65 | 0.030 |
Why?
| | Educational Status | 1 | 2016 | 464 | 0.030 |
Why?
| | Raltegravir Potassium | 1 | 2013 | 19 | 0.030 |
Why?
| | DNA, Ribosomal | 1 | 2013 | 94 | 0.030 |
Why?
| | Gray Matter | 1 | 2014 | 87 | 0.030 |
Why?
| | Inositol | 1 | 2013 | 25 | 0.030 |
Why?
| | Skin | 1 | 2018 | 765 | 0.030 |
Why?
| | Bronchoalveolar Lavage | 1 | 2013 | 92 | 0.020 |
Why?
| | Hepatitis B Surface Antigens | 1 | 2013 | 23 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2024 | 5909 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 625 | 0.020 |
Why?
| | Phenotype | 2 | 2014 | 3177 | 0.020 |
Why?
| | Kinetics | 1 | 1996 | 1655 | 0.020 |
Why?
| | Oligopeptides | 1 | 2014 | 275 | 0.020 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2015 | 261 | 0.020 |
Why?
| | Medication Adherence | 1 | 2017 | 513 | 0.020 |
Why?
| | Global Health | 1 | 2015 | 387 | 0.020 |
Why?
| | Risk | 1 | 2015 | 907 | 0.020 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2016 | 266 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2014 | 2608 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2015 | 439 | 0.020 |
Why?
| | Cause of Death | 1 | 2014 | 441 | 0.020 |
Why?
| | White Matter | 1 | 2014 | 148 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2012 | 128 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 1993 | 370 | 0.020 |
Why?
| | Hypertension, Pulmonary | 1 | 2003 | 1942 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2011 | 25 | 0.020 |
Why?
| | Zebrafish | 1 | 2016 | 504 | 0.020 |
Why?
| | Blood Coagulation | 1 | 2013 | 269 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 599 | 0.020 |
Why?
| | Psychological Tests | 1 | 2012 | 136 | 0.020 |
Why?
| | Glutamic Acid | 1 | 2013 | 256 | 0.020 |
Why?
| | Data Collection | 1 | 2014 | 662 | 0.020 |
Why?
| | Visual Acuity | 1 | 2014 | 447 | 0.020 |
Why?
| | Headache | 1 | 2012 | 153 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 463 | 0.020 |
Why?
| | Mood Disorders | 1 | 2012 | 141 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1197 | 0.020 |
Why?
| | Biological Specimen Banks | 1 | 2011 | 99 | 0.020 |
Why?
| | Hospitalization | 1 | 2021 | 2264 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2014 | 584 | 0.020 |
Why?
| | Pyridines | 1 | 2014 | 557 | 0.020 |
Why?
| | Suicide, Attempted | 1 | 2014 | 394 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1793 | 0.020 |
Why?
| | Mozambique | 1 | 2010 | 7 | 0.020 |
Why?
| | Social Support | 1 | 2014 | 633 | 0.020 |
Why?
| | Calcium | 1 | 2016 | 1192 | 0.020 |
Why?
| | North America | 1 | 2011 | 307 | 0.020 |
Why?
| | Pyrimidinones | 1 | 2010 | 122 | 0.020 |
Why?
| | Antitubercular Agents | 1 | 2011 | 207 | 0.020 |
Why?
| | Gene Expression | 1 | 1995 | 1492 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 1027 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 434 | 0.020 |
Why?
| | Neuroglia | 1 | 2010 | 173 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2018 | 2007 | 0.020 |
Why?
| | Thalamus | 1 | 2010 | 120 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2010 | 363 | 0.020 |
Why?
| | Students, Medical | 1 | 2014 | 369 | 0.020 |
Why?
| | Organ Size | 1 | 2010 | 481 | 0.020 |
Why?
| | Caspase 7 | 1 | 2008 | 22 | 0.020 |
Why?
| | Mental Health | 1 | 2015 | 759 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 2075 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2008 | 126 | 0.020 |
Why?
| | Bone Morphogenetic Protein 4 | 1 | 2008 | 43 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 112 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2012 | 308 | 0.020 |
Why?
| | Caspase 3 | 1 | 2008 | 250 | 0.020 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2006 | 51 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 951 | 0.020 |
Why?
| | Fluorides | 1 | 2006 | 49 | 0.020 |
Why?
| | Polyurethanes | 1 | 2006 | 38 | 0.020 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 11 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 761 | 0.020 |
Why?
| | Methacrylates | 1 | 2006 | 121 | 0.020 |
Why?
| | Risk Assessment | 1 | 2015 | 3508 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2006 | 363 | 0.010 |
Why?
| | Computer Simulation | 1 | 2010 | 1015 | 0.010 |
Why?
| | Alleles | 1 | 2007 | 891 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 748 | 0.010 |
Why?
| | Guanosine Tetraphosphate | 1 | 1983 | 5 | 0.010 |
Why?
| | Cerulenin | 1 | 1983 | 1 | 0.010 |
Why?
| | Linolenic Acids | 1 | 1983 | 1 | 0.010 |
Why?
| | Linoleic Acids | 1 | 1983 | 7 | 0.010 |
Why?
| | Light | 2 | 1983 | 395 | 0.010 |
Why?
| | Oleic Acids | 1 | 1983 | 12 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2903 | 0.010 |
Why?
| | Linoleic Acid | 1 | 1983 | 45 | 0.010 |
Why?
| | Oleic Acid | 1 | 1983 | 42 | 0.010 |
Why?
| | Nucleotides | 1 | 1983 | 127 | 0.010 |
Why?
| | Fatty Acids, Unsaturated | 1 | 1983 | 98 | 0.010 |
Why?
| | Membrane Lipids | 1 | 1983 | 91 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1828 | 0.010 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2001 | 38 | 0.010 |
Why?
| | Bacteriological Techniques | 1 | 1981 | 67 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7923 | 0.010 |
Why?
| | Cardiac Catheterization | 1 | 2003 | 540 | 0.010 |
Why?
| | Apoptosis | 1 | 2008 | 2576 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1739 | 0.010 |
Why?
| | HIV Seronegativity | 1 | 1998 | 30 | 0.010 |
Why?
| | Prognosis | 1 | 2006 | 4080 | 0.010 |
Why?
| | Infant | 1 | 2012 | 9843 | 0.010 |
Why?
| | Substance Abuse, Intravenous | 1 | 1998 | 122 | 0.010 |
Why?
| | Antipyrine | 1 | 1996 | 12 | 0.010 |
Why?
| | Drug Resistance, Microbial | 1 | 1996 | 65 | 0.010 |
Why?
| | Drug Interactions | 1 | 1996 | 406 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 1996 | 582 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 1981 | 82 | 0.000 |
Why?
| | Cell Division | 1 | 1981 | 798 | 0.000 |
Why?
|
|
Campbell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|